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ABSTRACT (250 max) 37 
Objective: Symptoms of Eustachian tube (ET) dysfunction are seldom assessed in patients with 38 
chronic rhinosinusitis (CRS). The SNOT-22 quality-of-life tool includes two questions that 39 
specifically screen for symptoms of ET dysfunction (‘Ear Fullness’; ‘Ear Pain’). The purpose of 40 
this study was to determine the extent to which these ET symptoms were present in patients with 41 
CRS, and whether these symptoms respond to endoscopic sinus surgery (ESS). 42 
Study design: Prospective cohort studies 43 
Setting: Secondary and tertiary care centres 44 
Subjects & Methods: SNOT-22 data collected at time of recruitment into IRB-approved clinical 45 
trials or case-control studies in CRS was pooled to provide a cross section of the frequency and 46 
severity of ET dysfunction in CRS patients. When applicable to the trials, the SNOT-22 was 47 
repeated at least 3 months following ESS.  48 
Results: Five trials rendering 131 patients were available for assessment. The control group 49 
comprised of 251 participants. ‘Ear Fullness’ of ≥1 was reported in 80/131 CRS patients 50 
compared to 45/251 control patients, (Mean=3.08 vs. 1.84; p<0.001). ‘Ear Pain’ of ≥1 was 51 
reported in 39/131 CRS patients compared to 33/251 control patients (Mean=2.31 vs.1.82; 52 
p=0.042). Following ESS, mean ‘Ear Fullness’ and ‘Ear Pain’ scores decreased to 1.17 and 0.73, 53 
respectively (p < 0.001). 54 
Conclusion: Symptoms suggestive of ET dysfunction are frequent in CRS, and for most patients 55 
the symptoms will decrease following intervention, to a level comparable with a non-CRS 56 
population. Patients' whose ET symptoms do not respond to ESS may represent a target 57 
population for emerging therapeutic options for ET dysfunction. 58 
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 59 
INTRODUCTION (manuscript max is 3000 words – Intro to Conclusion) 60 
 The Eustachian tube (ET) provides the physiological functions of middle ear pressure 61 
equalization, protection, and clearance. ET dysfunction can be divided into two categories: 62 
functional – defined as the inability to actively dilate the tube; or mechanical – defined as 63 
secondary to inflamed mucosa, middle ear disease, hypertrophic adenoids, nasopharyngeal 64 
neoplasm, and/or polyps. Tubal integrity and susceptibility to dysfunction are also known to be 65 
influenced by allergy and sinonasal disease, especially when these disorders are chronic. Chronic 66 
rhinosinusitis (CRS) is one of the most common inflammatory diseases of the nose and paranasal 67 
sinuses affecting up to 10% of the population1,2. The Sino-Nasal Outcome Test (SNOT-22) is a 68 
self-reported symptom-based rhinosinusitis outcome measure tool that is widely accepted and 69 
validated for patients with CRS3. Patients complete the questionnaire by grading their symptom 70 
severity from 0 (not a problem) to 5 (problem as bad as it can be). The SNOT-22 includes two 71 
questions related to ET dysfunction, that of “ear fullness” and “ear pain”. These symptoms can 72 
be quite debilitating to patients4, leading to increased absenteeism from work or hindered social 73 
interactions, and thus deserve further investigation. There have been reports that rhinosinusitis 74 
and ET dysfunction can be associated and that endoscopic sinus surgery (ESS) can alleviate such 75 
symptoms5, although it remains to be thoroughly studied. 76 
 The aims of this study were to determine the prevalence and severity of symptoms 77 
associated with ET dysfunction in CRS patients compared to a control group without known 78 
otologic disease or CRS, and to evaluate the evolution of these symptoms in CRS patients 79 
following ESS. 80 
 81 
82 
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METHODS 83 
Chronic rhinosinusitis patients 84 
 SNOT-22 data from five institutional review-board-approved prospective clinical trials or 85 
case-control studies including both CRS patients with and without nasal polyposis were collected 86 
and evaluated. Patients had to have had at least a SNOT-22 completed on the day of surgery to 87 
be eligible for this study, while post-ESS SNOT-22 scores were collected from the same patients, 88 
when available, at least 3 months following ESS. All patients included in these clinical trials 89 
were considered patients at ‘high-risk’ of CRS recurrence according to our group’s previously 90 
described criteria6.  91 
Control group 92 
 Control group SNOT-22 data were retrieved from the Chronic Rhinosinusitis 93 
Epidemiology Study (CRES)7,8 and the ongoing Socioeconomic Cost of Chronic Rhinosinusitis 94 
Study (SocCoR)9 database originating in the United Kingdom. Family and friends of patients 95 
attending otolaryngology outpatient clinics and hospital and university staff were recruited as 96 
controls. This non-CRS population had no self-reported otologic or nasal disease, active 97 
treatment for chronic conditions, nor any hospital admissions in the preceding 12 months. 98 
Statistical analyses 99 
All data were tabulated using Microsoft Excel and all statistical analyses were performed 100 
using STATA 13.1 (STATACorp LP, College Station, TX). Absolute and relative frequencies 101 
are presented for categorical and ordinal variables. A two-tailed Pearson Chi-square or Fisher’s 102 
exact test was used to compare the prevalence and proportion of ET dysfunction symptoms 103 
between CRS and control groups. Comparison of symptom severity and overall SNOT-22 scores 104 
between groups and before and after ESS were evaluated using a two-sample Student T-test with 105 
unequal variances. For all statistical analyses, a p<0.05 was considered statistically significant. 106 
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RESULTS 107 
Demographics  108 
 A total of 131 patients at ‘high-risk’ of CRS recurrence were included in the CRS group 109 
and completed a SNOT-22 on the day of surgery. The control group comprised of 251 110 
participants having completed the SNOT-22 questionnaire on a single occasion. 111 
Table 1: Demographics and SNOT-22 findings 112 
 113 
 CRS group (N=131) Control group (N=251) P value 
Age (range) 52.7 (21-86) 47.5 (19-80)  
Female 52 143 
<0.001 
Male 79 96 
SNOT-22 (SD) 46.4 (20.6) 12 (13.6) <0.001 
No. patients with Ear fullness ≥1 
(%) 
80 (61.1%) 45 (17.9%) <0.001 
No. patients with Ear pain ≥1 
(%) 
39 (29.8%) 33 (13.2%) <0.001 
Mean Ear fullness symptom 
score if Ear fullness ≥1 (SD) 
3.08 (1.25) 1.84 (0.79) <0.001 
Mean Ear pain symptom score if 
Ear pain ≥1 (SD) 
2.31 (0.95) 1.82 (0.5) 0.042 
 114 
 115 
SNOT-22 according to ear symptom in CRS patients 116 
 The mean SNOT-22 score for CRS patients with a score of ≥1 for ‘ear fullness’ was 117 
significantly higher than in CRS patients with a score of 0 (53.2 vs. 35.8; p<0.001). Similarly, 118 
CRS patients with a score of ≥1 for ‘ear pain’ had a significantly higher overall SNOT-22 score 119 
than CRS patients with a score of 0 (63.4 vs. 39.2; p<0.001). 120 
Evolution of ‘ear fullness’ 121 
 Of the 80 CRS patients with a score of ≥1 for ‘ear fullness’, 66 (82.5%) completed a 122 
SNOT-22 score between 3 and 4 months post-ESS. Mean ear fullness score statistically 123 
significantly decreased post-ESS to 1.17 (Figure 1), while 78.8% (52 of 66) reported an 124 
improvement in their ‘ear fullness’ score (mean improvement =2.5; range 1 to 5). Five patients 125 
(7.6%) reported symptom deterioration. 126 
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Evolution of ‘ear pain’ 127 
 Of the 39 CRS patients with a score of ≥1 for ‘ear pain’, 30 (76.9%) completed a SNOT-128 
22 score between 3 and 4 months post-ESS. Mean ear pain score statistically significantly 129 
decreased post-ESS to 0.73 (Figure 2), while 73.3% (22 of 30) reported an improvement in their 130 
‘ear fullness’ score (mean improvement =2.2; range 1 to 3). Three patients (10%) reported 131 
symptom deterioration. 132 
 133 
DISCUSSION 134 
 The current literature on ET dysfunction symptoms in patients with CRS is very limited. 135 
To our knowledge, this is the first study where ET dysfunction symptoms are prospectively 136 
evaluated and compared to a control group. Our findings reveal that symptoms suggestive of ET 137 
dysfunction are quite frequent in patients with CRS who fail maximal medical therapy and 138 
require ESS. More specifically, ‘ear fullness’ was a reported symptom in close to two thirds of 139 
patients, while ‘ear pain’ was reported in one third of CRS patients. These rates are significantly 140 
higher than Stoikes et al.5’s previously published findings (42% and 15% respectively). 141 
Furthermore, compared to the control group, when present both ‘ear fullness’ and ‘ear pain’ were 142 
significantly more prevalent and debilitating in CRS patients. Overall, it is clear that the 143 
prevalence of ET dysfunction in CRS has been greatly underappreciated, particularly in patients 144 
with severe disease.  145 
 Our second significant finding is the important treatment effect CRS patients had 146 
following ESS. Approximately 75% of reported ‘ear fullness’ and ‘ear pain’ had a favourable 147 
evolution post-ESS, with a mean improvement of more than 2 points on 5. These findings are 148 
slightly inferior to Stoikes et al.5’s findings (84.3% and 84%, respectively), although one must 149 
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consider the important recall bias and variability of post-ESS response timeframe of their 150 
retrospective study. Others have demonstrated the improvement of ear-associated SNOT-22 151 
symptoms without however providing a detailed categorisation10,11. 152 
Limitations 153 
 The proportion of females were significantly higher in the control group, and as it has 154 
been described in the literature, females tend to report higher SNOT-22 scores7. This 155 
unfortunately can hinder our group comparability. However, when males and females average 156 
SNOT-22 scores were compared within each group, both CRS and control group females had 157 
proportionally higher scores. Overall, the effect of this inter-group difference can only lead to an 158 
underestimation of the symptoms in the CRS group, which in turn strengthens the already 159 
significant findings we have reported. Furthermore, it is important to note that our follow-up 160 
period was short and we therefore are unable assess the long-term effect of ESS on ET 161 
dysfunction-associated symptoms. 162 
Future directions 163 
 Although this prospective study on ET dysfunction-associated symptoms demonstrates 164 
the effect CRS can have on such symptoms, a more thorough evaluation of ET dysfunction with 165 
the Eustachian Tube Dysfunction Questionnaire (ETDQ-7)12 would be most appropriate. 166 
Furthermore, what remains to be addressed is the management of CRS patients with persistent 167 
and debilitating ET dysfunction symptoms, even following ESS where there remains a 168 
prevalence of 7.6% for ear fullness and 10% for ear pain). Alternative management is available 169 
and should be considered; one of these may be the novel surgical technique of ET balloon 170 
dilatation that has been shown to be a possible therapeutic option13 but remains to be validated 171 
with RCTs and long-term follow-up studies. 172 
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 173 
CONCLUSION 174 
 Symptoms suggesting ET dysfunction have been underestimated in the CRS population, 175 
especially in patients with severe disease. Our findings depict the substantial prevalence of ‘ear 176 
fullness’ and ‘ear pain’ in patients undergoing ESS for CRS, compared to a control population, 177 
while also demonstrating the strong positive treatment effect of ESS on these symptoms. We 178 
suggest that further study into ET dysfunction in CRS is needed to better understand the origin of 179 
these symptoms and to evaluate ideal treatment options for patients whose symptoms do not 180 
respond to surgical treatment of CRS. 181 
 182 
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Figure 1: Evolution of mean ear fullness score following endoscopic sinus surgery 234 
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 235 
 236 
Figure 2: Evolution of mean ear pain score following endoscopic sinus surgery 237 
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